Trump tariffs and changes at the FDA with David Lennarz

Key takeaways from this podcast:

• Companies are breaking out the Covid playbook and shoring up relationships with alternative sources for goods 
• Moving production to the US takes time and capital and may be out of reach for small and medium-sized companies
• Many companies may turn away from the US toward growing Asian markets
• Staffing cuts could impact FDA product reviews, approvals, and guidance documents 
• FDA under RFK Jr. may move to simplify product labels, increase GRAS oversight and eliminate user fees